Bladder cancer is a common tumour of the urinary system, and more than 90% is urothelial carcinoma. Therefore, it is important for discovering the key target genes and molecules of bladder tumour cell metastasis and invasion. Our research initially explored the regulation of deltaN p63 on the progression and metastasis of bladder cancer and found that deltaN p63 can influence the occurrence of EMT through PTEN and ultimately regulate the growth and metastasis of bladder cancer. In summary, this study identified a new EMT regulator, deltaN p63, further revealed the mechanism of the invasion and metastasis of bladder cancer cells, and provided a theoretical basis for finding new target molecules and drugs to treat bladder cancer. In conclusion, this study will further reveal the mechanism of tumour cell invasion and metastasis and provide a theoretical basis for cancer treatment to find new target molecules and drugs.

No abstract

Objective To explore the short-term efficacy of neoadjuvant endocrine therapy (NET) for localized prostate cancer and preliminary exploration of NET in patients with bone metastases. Methods Analyze clinical data of patients undergoing radical prostatectomy (RP) in the First Affiliated Hospital of Chongqing Medical University from January 2017 to January 2021 retrospectively. Patients with localized prostate cancer undergoing NET+RP were selected as the experimental group. The ones who only received RP were chosen as the control group, and the peri- and post-operative outcomes such as down-staging, pathological complete response, positive margin, intraoperative blood loss, and operation time were compared between the two groups. In addition, collect the information of patients with bone metastatic prostate cancer, excluding organ metastases, who received NET+RP over the same time-period and analyzed the short-term efficacy and quality of life. Results In the experimental group, there were more down-staging (13.08% vs. 4.67%, P=0.031), more pathological complete response (12.15% vs. 0.93%, P=0.001), less positive margin (9.35% vs. 29.91%, P< 0.001) and less blood loss (171.45±16.19 vs. 177.76±23.28, P=0.022). NET+RP also showed a satisfying short-term efficacy in patients with bone metastases, with well quality of life. Conclusion NET combined with RP can provide good short-term prognosis and patient satisfaction in patients with prostate cancer, and it is a potential option for patients with bone metastases without organ metastases.

Background Several groups proved kidney‐sparing surgery (KSS) had equivalent oncological outcomes compared with radical nephroureterectomy (RNU) for the low‐risk upper urinary tract urothelial carcinoma (UTUC) patients. Whereas, the clinical efficacy of KSS for high‐risk UTUC, especially for distal high‐risk ureteral carcinoma, remains unclear. Objective To evaluate the feasibility of KSS for patients with distal high‐risk ureter cancer. Materials and methods Our study included 22 patients who diagnose the distal high‐risk ureter cancer and underwent KSS between May 2012 and July 2021 in the First Affiliated Hospital of Chongqing Medical University. Overall survival (OS), confirmed as the primary endpoint of present study, was assessed by a blinded independent review committee (BIRC). The secondary endpoints included the postoperative SF‐36 (the short form 36 health survey questionnaire) score, progression‐free survival (PFS), postoperative complications, and so on. Results Overall, 17 (77.3%) and 5 (22.7%) patients underwent segmental ureterectomy (SU) and endoscopic ablation (EA), respectively. By the cut‐off date, the mean OS was 76.3 months (95% Cl: 51.3–101.1 months) and the mean PFS was 47.0 months (95% Cl: 31.1–62.8 months), respectively. And the SF‐36 score in a majority of patients was >300 (90.9%). Conclusion This is a daring endeavor to explore the clinical efficacy of KSS in distal high‐risk ureter cancer based on the high‐risk UTUC criteria, which shows satisfactory results in the long‐term prognosis and operation‐associated outcomes. However, future randomized or prospective multicenter studies are necessary to validate our conclusions.

Background: Primary aldosteronism (PA) is one of the most common causes of secondary hypertension and is potentially curable. However, a large number of patients still undergo persistent hypertension (PHT) after unilateral adrenal surgery. This research retrospectively studied the factors associated with this clinical difficulty and established a prediction model for the postoperative PHT; Methods: 353 patients from 2014 to 2021 with PA undergoing unilateral adrenal surgery were enrolled in this study. Clinical and biochemical characteristics were reviewed and the associating factors were examined using univariate and multivariate analysis. A nomogram-based prediction model was established correspondingly; results: 46.2% (163/190) of patients had post-surgical PHT. Multivariate analysis suggested that BMI≥25, diabetes, duration of hypertension, male gender, and ARR were independent predictors of PHT after surgery. The prediction model based on the nomogram showed good discrimination ability (the C index of the training group and the validation group were 0.783 and 0.769, respectively), and the calibration curves were good as well. Clinical usefulness was quantified using the decision curve analysis (DCA); Conclusion: This nomogram is an integration of the clinical and biochemical data of patients before surgery, and is a reliable tool with high accuracy for predicting the postoperative PHT in patients with PA.